alisol C 23-acetate: isolated from Alismatis Rhizoma; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 14036813 |
| CHEMBL ID | 4441811 |
| MeSH ID | M0427924 |
| Synonym |
|---|
| CS-3652 |
| 26575-93-9 |
| alisol c monoacetate |
| AC-35112 |
| HY-N0856 |
| alisol c 23-acetate |
| alisol c (23-acetate) |
| AKOS030526757 |
| 11beta-hydroxy-24,25-epoxy-3,16-oxo-protost-13(17)-en-23-yl acetate |
| mfcd23379923 |
| TF3DV2XK24 , |
| (8.alpha.,9.beta.,11.beta.,14.beta.,23s,24r)-23-(acetyloxy)-24,25-epoxy-11-hydroxydammar-13(17)-ene-3,16-dione |
| 23-o-acetylalisol c |
| (1s,3r)-1-((r)-3,3-dimethyloxiran-2-yl)-3-((5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-3,16-dioxo-2,3,4,5,6,7,8,9,10,11,12,14,15,16-tetradecahydro-1h-cyclopenta(a)phenanthren-17-yl)butyl acetate |
| alisol c 23-monoacetate |
| 8.alpha.,9.beta.,14.beta.-dammar-13(17)-ene-3,16-dione, 24,25-epoxy-11.beta.,23-dihydroxy-, 23-acetate, (23s,24r)- |
| dammar-13(17)-ene-3,16-dione, 23-(acetyloxy)-24,25-epoxy-11-hydroxy-, (8.alpha.,9.beta.,11.beta.,14.beta.,23s,24r)- |
| 23-o-acetylalisol c;alisol c monoacetate |
| MS-29789 |
| [(1s,3r)-1-[(2r)-3,3-dimethyloxiran-2-yl]-3-[(5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-3,16-dioxo-2,5,6,7,9,11,12,15-octahydro-1h-cyclopenta[a]phenanthren-17-yl]butyl] acetate |
| CHEMBL4441811 , |
| bdbm50528893 |
| dammar-13(17)-ene-3,16-dione, 23-(acetyloxy)-24,25-epoxy-11-hydroxy-, (8alpha,9beta,11beta,14beta,23s,24r)- |
| 8alpha,9beta,14beta-dammar-13(17)-ene-3,16-dione, 24,25-epoxy-11beta,23-dihydroxy-, 23-acetate, (23s,24r)- |
| unii-tf3dv2xk24 |
| (8alpha,9beta,11beta,14beta,23s,24r)-23-(acetyloxy)-24,25-epoxy-11-hydroxydammar-13(17)-ene-3,16-dione |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Bile acid receptor | Homo sapiens (human) | EC50 (µMol) | 2.1000 | 0.0040 | 1.4191 | 10.0000 | AID1609537 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleoplasm | Bile acid receptor | Homo sapiens (human) |
| chromatin | Bile acid receptor | Homo sapiens (human) |
| euchromatin | Bile acid receptor | Homo sapiens (human) |
| receptor complex | Bile acid receptor | Homo sapiens (human) |
| RNA polymerase II transcription regulator complex | Bile acid receptor | Homo sapiens (human) |
| nucleus | Bile acid receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1609537 | Transactivation of FXR (unknown origin) transfected in HepG2 cells co-expressing pBSEP/pGL4.74 incubated for 24 hrs by luciferase reporter gene assay | 2019 | European journal of medicinal chemistry, Nov-15, Volume: 182 | Highly potent non-steroidal FXR agonists protostane-type triterpenoids: Structure-activity relationship and mechanism. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.20) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||